Lipoprotein-associated coagulation inhibitor (LACI) inhibits activated Factor X (Xa) directly and, in an Xa-dependent fashion, inhibits Factor VIJa-tissue factor (TF), presumably by forming a quaternary Xa-LACI-VIIa-TF complex. LACI isolated from the conditioned media of HepG2 cells grown in the presence of [32P]orthophosphate was observed to be covalently phosphorylated. Dephosphorylation of 32P-LACI with phosphatase resulted in an almost complete removal of the radiolabel. Phosphoamino acid analysis of the purified 32P-LACI established that the phosphorylation occurred on (a) serine residue(s). At its N-terminus, LACI contains a cluster of acidic residues C-terminal to the serine-2 residue. Such a site is characteristic of the sites phosphorylated by casein kinase II (CKII) in protein substrates. Edman degradation of endogenously labelled 32P-LACI revealed that the serine-2 residue was a major site of phosphorylation. Phosphorylation of purified LACI by bovine CKII was observed to occur in vitro; amino acid sequence analysis demonstrated that CKII phosphorylated LACI at the serine-2 residue. Recombinant LACI expressed from mouse C127 fibroblasts transfected using a bovine-papilloma-virus expression vector was also found to be endogenously phosphorylated. By using site-directed mutagenesis, an altered form of LACI was produced in which the serine-2 residue had been changed to alanine. This altered LACI, although expressed in similar quantity to the wild-type LACI, was not detectably phosphorylated. Using the altered LACI in functional studies demonstrated that a serine residue at position 2, and thus the phosphorylation of this site, was not essential for LACI's inhibition of Xa and VIIa-TF activities.
INTRODUCTION
Upon vascular injury, blood coagulation is initiated when Factor VIla, a plasma proteinase, is exposed to, and combines with, its essential cofactor tissue factor (TF). The VIIa-TF complex proteolytically activates its substrate Factors IX and X [1] [2] [3] [4] [5] , which, through a cascade of events, leads eventually to the generation of a fibrin clot.
Lipoprotein-associated coagulation inhibitor (LACI) is associated with plasma lipoproteins and is a potent inhibitor of the VIIa-TF complex [6] [7] [8] [9] . LACI has been purified by our laboratory from a human hepatoma cell line (HepG2) [10] and shown to bind to, and inhibit, activated Factor X (Xa) directly and to inhibit VIIa-TF activity in an Xa-dependent fashion, presumably by forming an Xa-LACI-VIIa-TF quaternary complex [11] . Further investigation demonstrated that, although LACI bound to and inhibited Xa which lacked its y-carboxyglutamic acid (Gla)-containing domain, VIIa-TF activity was not inhibited by LACI in the presence of Gla-do?mainless Xa [11] .
The primary amino acid sequence of LACI, deduced from cDNA sequences [12, 13] , shows that LACI contains three tandem Kunitz-type proteinase-inhibitory domains located between a cluster of negatively charged amino acid residues at its Nterminus and a cluster of positively charged residues near its Cterminus. Recent studies, employing site-directed mutagenesis to produce altered forms of LACI, have demonstrated LACI's first Kunitz domain (as it occurs from the N-terminus) probably binds to VIIa's active site, whereas the second Kunitz domain binds to the active site of Xa [14] . Primary amino acid sequence analysis indicates three potential sites for N-linked glycosylation, and studies indicate that at least two of these sites are glycosylated [15] . The fraction of plasma LACI associated with high-density lipoproteins ( -40 %) has recently been shown to be covalently attached through disulphide linkage(s) to apolipoprotein A-II [16] . No LACI purification from 32P-labelled-HepG2-cells' serum-free conditioned medium Confluent cells were incubated with 32P in serum-free, phosphate-free, Dulbecco's modified Eagle's medium. Cells received 5 mCi of 32P in 10 ml of medium/75 cm2 dish and were incubated at 37°C for 3 days. LACI was purified from the cells' conditioned medium using a previously described three-step purification procedure which utilizes bovine Xa-affinity chromatography [17] .
Phosphatase treatments
Purified LACI was dialysed into 20 mM-NH4HCO3, pH 8.0, and aliquots were dried with a SpeedVac Concentrator (Savant Instruments, Farmingdale, NY, U.S.A.). LACI was dissolved in 50 mM-sodium acetate, pH 5.0, for acid phosphatase treatment or 50 mM-Tris/HCl/100 mM-NaCl/5 mM-MgCl2, pH 8.0, for alkaline phosphatase treatment. The appropriate phosphatase was added and the samples were incubated for 2 h at 30 'C. The samples were analysed by SDS/PAGE, followed by autoradiography. For functional studies, the LACI was repurified using bovine Xa-affinity chromatography to remove the phosphatase activity, dialysed and concentrated as described above.
Phosphorylation of LACI by CKII
To assay for the incorporation of [32PJphosphate into LACI, purified LACI (1.6 /zM) was incubated at 30 'C with CKII (1 nM) in 50 ,l of 50 mM-Tris/HCl/150 mM-NaCl/l0 mM-MgCl2, pH7.6, containing 51Ci of [y-32P]ATP (3000 Ci/mmol). To monitor the incorporation, 10 ,1 aliquots were removed at 15 min intervals, immediately spotted on to phosphocellulose paper (Whatman P8 1), washed in 150 mM-phosphoric acid and counted for radioactivity [18] . At 45 min, 5,1 aliquots were removed from the assay mixtures and added to 5,ul of SDS/PAGE 4 x sample buffer [60 mM-Tris/HCl/2 % (w/v) SDS/25 % (v/v) glycerol, pH 6.8] to stop the reactions. Samples were electrophoresed on 15 % (w/v) polyacrylamide gels and analysed by autoradiography. To 32P-label the LACI for sequencing purposes, the above reaction was scaled up 7-fold and incubation was allowed to proceed for 2 h, after which the 32P-LACI was separated from free label by using bovine Xa-affinity chromatography followed by further purification using gel-sieve chromatography [17] . cycle, was counted directly for radioactivity, to determine 32P release [20] . The second method employed the split-filter technique of Wang et al. [21] . In this method 32P-LACI was applied to a glass-fibre sequencing filter coated with Polybrene. The filter was cut into four equal sections and gas-phase sequencing was performed. A section of the filter was removed after a blank (begin) cycle and after the first three sequencing cycles. Free 32P and protein were extracted from the filter sections with 88 % formic acid, dried and resuspended in 20 u1 of pH 3.5 buffer [pyridine/acetic acid/water (1:10:189, by vol.)]. These samples were spotted on to cellulose t.l.c. plates, which were then electrophoresed at 500 V for I h in pH 3.5 buffer. The plates were analysed by autoradiography [19] .
Construction and transfection of the LACI(Ala-2) mutant
The construction and transfection of recombinant wild-type LACI [LACI(wt)] has been described [13] . The same LACI cDNA insert engineered into the bovine-papilloma-virus vector for expression in C127 fibroblasts was also ligated into Ml13mpl 8, and site-directed mutagenesis was performed [22] to convert the TCT codon encoding for serine at position 2 (residues are numbered from the N-terminus of mature LACI) into a GCT codon encoding for alanine. This mutant LACI cDNA was engineered into the bovine-papilloma-virus expression vector and used to transfect C127 fibroblasts as described in [13] .
SDS/PAGE and Western blotting SDS/PAGE was performed by the method of Laemmli [23] using a 15 % separating gel (4 % stacking gel). Western blotting was performed as previously described, using a rabbit polyclonal anti-LACI IgG fraction [24] .
Functional assays of LACI LACI(wt) and LACI(Ala-2) were assayed using the appropriate cloned cells' serum-free conditioned medium diluted in TBSA (100 mM-NaCl/50 mM-Tris/HCl/0.l % BSA, pH 7.4).
Alkaline-phosphatase-treated and CKII-phosphorylated LACI were repurified using Xa-affinity chromatography before assaying. The LACI concentration for each sample was determined in a particle-concentration immunofluorescence assay using two non-competitive anti-LACI monoclonal antibodies [25] . Xainhibitory activities were determined as previously described using 25 ng of bovine Xa/ml (final concn.) [13] . VIIa-TF inhibitory activities of the LACI's were measured by a 3H-IXactivation-peptide release assay as previously described [13] .
RESULTS

Phosphorylation of LACI by HepG2 cells
LACI purified from the serum-free conditioned medium of HepG2 cells incubated for 3 days in the presence of [32P]orthophosphate was found to be radiolabelled as determined by SDS/PAGE, followed by autoradiography (Fig. la, lanes 1  and 3) . The 32P incorporated into LACI was almost completely removed by treatment with either acid phosphatase or alkaline phosphatase (Fig. la, lanes 2 and 4) . Western-blot analysis demonstrated the phosphatase treatments were not accompanied by any detectable alterations in the quantity of LACI or in LACI's relative mobility in the gel system (Fig. lb) . Phospho amino acid analysis of purified 32P-LACI labelled by HepG2 cells revealed phosphorylation occurred on serine residue(s), but not on threonine or tyrosine residues (Fig. lc) Polybrene and subjected to gas-phase sequencing. A filter segment was removed after a blank (begin) cycle (lane 1) and after Edman degradation cycles 1 (lane 2), 2 (lane 3) and 3 (lane 4). Radioactivity was extracted from each segment with formic acid and analysed by thin-layer electrophoresis at pH 3.5. In lanes 3 and 4 the radioactivity migrating as Pi represents 52 % and 49 % of the total activity of each sample respectively, as determined by scraping the plate and measuring radioactivity. cognition site for phosphorylation by CKII exists at the serine-2 residue at LACI's N-terminus (see below). To determine if this site was phosphorylated, endogenously labelled 32P-LACI was subjected to sequencing by Edman degradation using a spinningcup sequencer. Fig. 2(a) shows the 32P radioactivity released after a blank (begin) cycle and six sequencing cycles. As expected for the serine-2 being phosphorylated, the peak release of 32p occurred after the second sequencing cycle (third cycle overall, including the begin cycle). The endogenously labelled LACI was sequenced a second time using the split-filter technique of Wang et al. [21] . Radioactivity was extracted from the pieces of sequencing filter removed after the begin cycle and the first, Vol. 270 second and third cycles of Edman degradation, and free 32p was separated from 32P-LACI by thin-layer electrophoresis. As the autoradiograph in Fig. 2(b) shows, free phosphate appears after the second sequencing cycle. Of the total radioactivity, 52 % and 49 % in cycles 3 and 4 respectively migrated as Pi as determined by scraping the plate's radioactive areas and counting. These results demonstrate serine-2 is a major site of phosphorylation in LACI by HepG2 cells.
Requirement of serine-2 for endogenous phosphorylation of LACI
To investigate further the phosphorylation of LACI, sitedirected mutagenesis was used to prepare a LACI mutant in which the serine-2 residue was changed to alanine. As previously described for recombinant LACI(wt), the mutant DNA was also introduced into the bovine-papilloma-virus vector pMON1 123 and co-transfected with pSV2neo into mouse C127 fibroblasts. A clone expressing the altered human LACI protein, designated LACI(Ala-2), was identified by Western-blot analysis (Fig. 3a) . LACI(wt) and LACI(Ala-2) were purified from serum-free conditioned media from their respective cells which had been incubated for 3 days in the presence of [32P]orthophosphate. The extent of incorporation of radioactivity into the respective LACIs is shown in the autoradiograph in Fig. 3 . Although both cell lines expressed roughly similar amounts of recombinant LACIs, only the LACI(wt) was 32P-labelled. Thus C 127 fibroblasts are capable of phosphorylating LACI, and the serine-2 residue of LACI is necessary for this phosphorylation to occur.
Phosphorylation of LACI by CKII in vitro
The serine-2 in LACI precedes five consecutive negatively charged amino acid residues. Such a site is characteristic of the sites phosphorylated by CKII in protein substrates [16] . The ability of CKII to catalyse the phosphorylation of purified LACI(HepG2) in vitro was investigated. The results in Fig. 4(a) demonstrate that LACI can be phosphorylated in vitro by CKII (lane 1) and that LACI does not undergo autophosphorylation (lane 2). The radiolabelled band observed in the kinase assay without LACI (lane 3) is characteristic of CKII undergoing autophosphorylation [26] . Phosphoamino acid analysis demonstrated that phosphorylation of LACI had occurred predominantly on serine residue(s) and only a trace of radiolabelled phosphothreonine was detected. [Although (a) Inhibition of Xa. Xa-inhibitory activities were determined as previously described [13] using 25 ng of bovine Xa/ml (final concn.). Samples are LACI(wt) (0) and LACI(Ala-2) (-) serum-free conditioned media diluted in TBSA. The LACI concentration for each serum-free conditioned medium was determined in a particleconcentration immunofluorescence assay [24] using two non-competitive anti-LACI monoclonal antibodies. (b) Inhibition ofVIIa-TF activity. VIIa-TF inhibitory activities were measured by a 3H-IXactivation peptide release assay [13] . Samples are as in (a).
Functional activities of the LACI(Ala-2) mutant Serum-free conditioned media were used to assess the ability of the LACI(Ala-2) molecules to inhibit Xa and VIIa-TF activities. As the results in Fig. 5 show, both LACI(wt) and LACI(Ala-2) were equally potent in inhibiting Xa and VIIa-TF activities. Likewise, alkaline-phosphatase-treated LACI possessed inhibitory activities similar to those of untreated LACI (results not shown). These results demonstrate that a serine residue at position 2 in LACI, and thus the phosphorylation of this site, is not necessary for the inhibition of Xa or VIIa-TF activities.
DISCUSSION P-Ser
In the present paper we demonstrate that LACI isolated from -P-Thr, P-Tyr HepG2 serum-free conditioned medium is covalently phosphorylated. Sequence analysis clearly identified the serine-2 residue as [31] and RNA polymerases I and II [32] by CKII have been reported to regulate activity. Assays with in vitro recombinant LACI(Ala-2) and alkaline-phosphatase-treated LACI indicate the phosphorylation state of LACI at the serine-2 residue is not required for LACI's inhibition of Xa or VIIa-TF activities. This is not unexpected, since we have previously shown that the first and second Kunitz domains of LACI are responsible for these activities [14] .
Human plasma LACI is associated with lipoproteins (lowdensity > high-density > very-low-density lipoproteins) [6, 8, 15] . 
